The global demand for Intravenous Immunoglobulin Market is presumed to reach the valuation of nearly USD XX MN by 2026 from USD XX MN in 2019 with a CAGR of XX% under the study period of 2020 - 2026.
Intravenous Immunoglobulin (IVIG) refers to a therapy that helps in treating patients with antibody deficiencies. It is a blood product made by immunoglobulin’s (antibodies) from the plasma of thousands of healthy people to fight infections. Immunoglobulin’s are glycoprotein’s which are produced from the plasma cells. As IVIG is prepared from plasma, it is highly purified so the chances of developing a blood-borne infection are exceptionally low. This therapy helps in treating a large number of diseases such as kawasaki disease, lupus, guillain-barre syndrome, myositis, chronic inflammatory demyelinating polyneuropathy (CIDP) and also immune deficiencies such as immune thrombocytopenia. In addition to this it is also used for treating some neurological diseases such as multiple sclerosis or myasthenia gravis.
The global Intravenous Immunoglobulin Market is majorly driven by growing elderly population, high prevalence of immunodeficiency diseases, growing number of hemophilic patients, increase in acceptance of IVIG treatments and rising investment in intravenous immunoglobulin medication projects. Increasing number of patients with immunodeficiency disorders is the major factor boosting the demand of Intravenous Immunoglobulin therapy. As per National Institute of Allergy and Infectious diseases (NIAID) there are over 200 different forms of primary immune deficiency diseases (PIDDs) and around 500,000 people in the United States suffering from such PIDDS.
The report covers Porter’s Five Forces Model, Market Attractiveness Analysis and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level.
Additionally, these tools also give inclusive assessment of each application/product segment in the global market of intravenous immunoglobulin.
The entire intravenous immunoglobulin market has been sub-categorized into component, application and end-user. The report provides an analysis of these subsets with respect to the geographical segmentation. This research study will keep marketer informed and helps to identify the target demographics for a product or service.
- Immunodeficiency Diseases
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Idiopathic Thrombocytopenic Purpura
- Myasthenia Gravis
- Multifocal Motor Neuropathy
- Inflammatory Myopathies
- Specific Antibody Deficiency
- Guillain-Barre Syndrome
- Homecare Settings
This section covers regional segmentation which accentuates on current and future demand for intravenous immunoglobulin market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand for individual application segment across all the prominent regions.
Global Intravenous Immunoglobulin Market Share by Region (Representative Graph)
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the intravenous immunoglobulin market include LFB Biotechnologies, Biotest, Octapharma, Grifols, CSL Behring, China Biologics Products, Kedrion Biopharma, BDI Pharma, Shire, CSL Behring. This section includes a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
This market research report has been produced by gathering information on the basis of primary and secondary research. Secondary research has been done by using various sources which include (but not limited to) Company Websites, Paid Data Sources, Technical Journals, Financial Reports, SEC Filings, and other different industry publications.
If specific information is required which is not currently within the scope of the report, it can be provided as a part of customization.